(B) relevant industry regulators and enti-
ties that utilize real-time reporting of trans-
actions, orders, or other activities with the goal 
of identifying suspicious activity, such as appro-
priate personnel from the Financial Crimes En-
forcement Network and money transfer indus-
try professionals. 
(d) MEETINGS.— 
(1) IN GENERAL.—The Task Force shall meet 
not less frequently than 4 times per year and at 
such other times as may be determined necessary by 
the Task Force. 
(2) INITIAL MEETING.—Not later than 60 days 
after the date of enactment of this Act, the Task 
Force shall hold the initial meeting of the Task 
Force. 
(e) PRELIMINARY ORDER EVALUATION PROGRAM.— 
(1) IN GENERAL.— 
(A) DESIGN.—Not later than 60 days after 
the date on which the Task Force holds the ini-
tial meeting required under subsection (d)(2), 
the Task Force shall begin to design a program 
in accordance with paragraph (2). 
(B) PURPOSE.—The program described in 
subparagraph (A) shall be designed to share 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
necessary data, in a limited capacity, with reg-
istrants in order to provide registrants with in-
formation to identify suspicious ordering in real 
time. 
(C) DEADLINE
FOR
COMPLETION.—Not 
later than 8 months after the date of enactment 
of this Act, the Task Force shall complete the 
design required under subparagraph (A). 
(2) REQUIREMENTS.— 
(A) IN GENERAL.—The program required 
under paragraph (1) shall establish a process 
for— 
(i) transitioning to a requirement to 
report in real time to the Attorney General 
under section 307(d) of the Controlled 
Substances Act (21 U.S.C. 827(d)) every 
sale, delivery, or other disposal by a reg-
istrant of any controlled substance; 
(ii) limited sharing in real time of Au-
tomation of Reports and Consolidated Or-
ders 
System 
(commonly 
known 
as 
‘‘ARCOS’’) data with registrants to share 
necessary data, in a limited capacity, with 
registrants in order to provide registrants 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
with information to identify suspicious or-
dering in real time; and 
(iii) ensuring data privacy, data de- 
identification, protection of trade secrets 
and purchasing history. 
(B) OTHER CONSIDERATIONS.—In design-
ing the program under paragraph (1), the Task 
Force shall take into consideration— 
(i) the inclusion of a waiver process 
for pharmacies and other registrants un-
able to transmit orders electronically on 
the date of enactment of this Act; 
(ii) a mechanism to ensure that the 
costs of running the program are not 
passed through to customers of registrants, 
unless the registrants are customers of 
other registrants; 
(iii) technical requirements for ensur-
ing that registrants may access all relevant 
de-identified data, with output provided in 
a standard database file format; and 
(iv) a mechanism to ensure that the 
program required to be designed under 
subparagraph (A) is updated based on 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
feedback from industry members and other 
relevant entities. 
(3) IMPLEMENTATION.—Not later than 1 year 
after the date of enactment of this Act, the Attorney 
General shall— 
(A) implement the program designed under 
paragraph (1) to collect and share in real time 
data for registrants to evaluate the orders of 
controlled substances from distributors to man-
ufacturers and from pharmacies to distributors; 
or 
(B) otherwise implement a program to col-
lect and share in real time data for drug manu-
facturers and distributors, by providing access 
to anonymized information to help drug manu-
facturers and distributors identify, report, and 
stop suspicious orders of controlled substances 
and reduce diversion rates. 
(4) RECOMMENDED
STATUTORY
AND
REGU-
LATORY CHANGES.—In designing the program re-
quired under paragraph (1), the Task Force— 
(A) shall submit to the Attorney General 
any recommendations for necessary amend-
ments to regulations of the Department of Jus-
tice relating to the requirements for ordering 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
schedule II controlled substances, so as to allow 
uniform electronic ordering of controlled sub-
stances in schedules II, III, IV, and V electroni-
cally through the program; and 
(B) may submit to Congress any rec-
ommendations for necessary legislative changes 
so that a real-time data analytics solution can 
be used across the United States. 
(5) RESPONSIBILITY
OF
REGISTRANTS.—All 
registered drug manufacturers and distributors shall 
be responsible for reviewing any information made 
available by the Attorney General and complying 
with any regulations regarding the program designed 
under paragraph (1) and implemented under para-
graph (3). 
(f) FUNDING.— 
(1) IN GENERAL.—The Attorney General, act-
ing through the Administrator, shall use amounts 
collected as fees for distributors and registrants 
under section 303 of the Controlled Substances Act 
(21 U.S.C. 823) and section 1007 of the Controlled 
Substances Import and Export Act (21 U.S.C. 957) 
to carry out this section. 
(2) OFFSET.— 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
(A) IN
GENERAL.—The Administrator 
may, on an equal basis and in accordance with 
subparagraph (B), increase the fees described 
in paragraph (1) for distributors and reg-
istrants to the extent necessary to defray the 
costs of this section. 
(B) TIERED
FEE.—The Administrator 
shall establish a tiered user fee for distributors 
and registrants in proportion to the volume of 
sales and purchases. 
(g) APPLICABILITY OF FACA.— 
(1) IN GENERAL.—Except as provided in para-
graph (2), the Federal Advisory Committee Act (5 
U.S.C. App.) shall apply to the Task Force. 
(2) TERMINATION.—The Task Force shall ter-
minate on the date on which the program is fully 
implemented under subsection (e)(3). 
(h) RULES OF CONSTRUCTION.—Nothing in this Act 
shall be construed as relieving any manufacturer, dis-
tributor, or other registrant from the responsibilities of 
the manufacturer, distributor, or other registrant, as the 
case may be, to— 
(1) identify, stop, and report suspicious orders; 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS
(2) maintain effective controls against diversion 
in accordance with section 303 of the Controlled 
Substances Act (21 U.S.C. 823); and 
(3) comply with the requirements established in 
section 1301.74(b) of title 21, Code of Federal Reg-
ulations, or any successor regulation thereto, with 
respect to suspicious orders. 
Æ 
VerDate Sep 11 2014 
19:41 Oct 31, 2019
Jkt 099200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6301
E:\BILLS\H4814.IH
H4814
pamtmann on DSKBC07HB2PROD with BILLS